Trial Profile
A phase I, open-label, randomized, three-way crossover trial evaluating the efficacy, safety, pharmacokinetics and tolerability of two fixed-dose combinations (FDC) of Darunavir/Cobicistat (G003 and G004) versus Darunavir and Ritonavir in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Cobicistat/darunavir (Primary) ; Darunavir; Ritonavir
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms TMC114IFD1001
- Sponsors Janssen Research & Development
- 05 Dec 2015 New trial record